Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
What's New in JAK Inhibitors
Description
This presentation discusses the latest advancements in Janus kinase (JAK) inhibitors, highlighting their role in treating previously underserved conditions such as vitiligo, alopecia areata, and hidradenitis suppurativa. The speaker emphasizes the promising landscape of new FDA-approved therapies, notably ruxolitinib for vitiligo and new oral JAK inhibitors, including bericitinib and ritlacitinib for alopecia areata. The mechanisms of action of JAK inhibitors are explained using a relatable analogy, with a focus on their selective inhibition and safety profiles. The safety monitoring protocols for patients on JAK inhibitors are also addressed, comparing them to biologic therapies. The presentation reviews clinical data demonstrating rapid itch relief in atopic dermatitis due to oral JAK inhibitors, underlining their effectiveness and safety over time. Updated findings on new JAK inhibitors for conditions such as psoriasis and vitiligo are presented, including ducravacitinib’s unique binding properties that result in fewer safety concerns. The speaker concludes by reinforcing the significant therapeutic potential of JAK inhibitors in dermatology, noting that the approvals provide new hope for managing these challenging conditions.
View moreConclusions
- The renaissance of JAK inhibitors has introduced exciting therapeutic options for previously treatment-resistant conditions such as vitiligo and alopecia areata.
- Multiple JAK inhibitors are now FDA approved for various inflammatory diseases, notably atopic dermatitis, alopecia areata, and vitiligo.
- Tofacitinib, the first JAK inhibitor approved, has been useful off-label for various conditions, while newer options have gained approval for specific conditions.
- Ruxolitinib is the first FDA-approved topical therapy for vitiligo, marking a significant advancement in its treatment.
- Baricitinib and upadacitinib are effective oral JAK inhibitors for atopic dermatitis, demonstrating rapid itch relief and sustained therapeutic effects.
- Safety data for JAK inhibitors indicate favorable profiles, with a low incidence of serious adverse events over extended periods.
- Ritlecitinib has shown promise in clinical trials for alopecia areata, establishing a new avenue for treatment of this condition.
- There is ongoing research to refine JAK inhibitor use, improve selectivity, and explore new therapeutic targets within the JAK-STAT signaling pathways.
- Combination therapy with JAK inhibitors and other modalities may enhance treatment outcomes for conditions like vitiligo.
- J Am Acad Dermatol. 2017 Apr; 76(4): 736-744. doi: 10.1016/j.jaad.2016.12.005
- Fridman JS, et al. J Immunol 2010;184:5298-307
- Schmieder GJ, et al. Br J Dermatol 2018;179:54-62
- Parmentier JM, et al. BMC Rheumatol 2018;2:23
- Simpson EL, et al. EADV 2019, D3T01.11; Silverberg JI, et al. JAMA Dermatol 2020 epub ahead of print
- Bieber T, et al. N Engl J Med 2021;384:1101-12
- Burmester GR, et al. Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis. RMD open. 2023 Feb 1;9(1):e002735.
- Hedderson MM, Asgari MM, Xu F, et al. Rates of cardiovascular events among patients with moderate-to-severe atopic dermatitis in an integrated health care system: A retrospective cohort study. Plos one. 2022 Nov 17;17(11):e0277469.
- Meyers KJ, Silverberg JI, et al. Risk of venous thromboembolism among patients with atopic dermatitis: a cohort study in a US administrative claims database. Dermatology and Therapy. 2021 Jun;11(3):1041-52.
- Liu LY, King BA. Ruxolitinib for the treatment of severe alopecia areata. J Am Acad Dermatol. 2019 Feb;80(2):566-568. doi: 10.1016/j.jaad.2018.08.040. Epub 2018 Sep 6. PMID: 30195572.